Invalidity dossier

US 10543179

Dosage regimen of an S1P receptor modulator

Current assignee: Novartis Pharmaceuticals Corp.

Added 8/21/2026, 6:49:08 PM

At a glanceNo PTAB challenges1 lawsuit on fileasserted by Novartis Pharmaceuticals Corp.

Active provider: DeepSeek · deepseek-v4-flash

Auto-generating section 1 of 8: Patent summary…

Each section takes ~30-60s with web-search grounding. Keep this tab open — sections will fill in below as they complete.

Patent summary

Title, assignee, inventors, filing/issue dates, abstract, and a plain-language overview of the claims.

Not generated yet. Click Generate to call the active LLM provider with the configured prompt.

Cases on file (1)

Group view →

Specific litigation cases in our database that name US patent 10543179. The free-form analysis below may also discuss cases beyond this list.

Litigation summary

Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.

Not generated yet. Click Generate to call the active LLM provider with the configured prompt.

Proceedings on file (0)

All PTAB activity →

AIA trial proceedings (IPR / PGR / CBM) filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced from the USPTO Open Data Portal and refreshed every six hours; each proceeding number deep-links to the PTAB E2E docket.

Current assignee: Novartis Pharmaceuticals Corp.

No PTAB proceedings on file. This patent has not been challenged via IPR, PGR, or CBM. The absence is itself a signal — well-asserted patents eventually attract IPRs. The LLM analysis below may surface filings the ODP feed hasn’t indexed yet.

PTAB challenges

AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.

Not generated yet. Click Generate to call the active LLM provider with the configured prompt.

Assignment history

Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.

Not generated yet. Click Generate to call the active LLM provider with the configured prompt.

Prior art

Earlier patents, publications, and products that may anticipate or render the claims unpatentable.

Not generated yet. Click Generate to call the active LLM provider with the configured prompt.

Obviousness

Combinations of prior art that suggest the claimed invention would have been obvious under 35 U.S.C. § 103.

Not generated yet. Click Generate to call the active LLM provider with the configured prompt.

Extensions

Patent term adjustments, term extensions, continuations, divisionals, family members, and expiration dates.

Not generated yet. Click Generate to call the active LLM provider with the configured prompt.

Derivative works

Defensive disclosure: derivative variations of each claim designed to render future incremental improvements obvious or non-novel.

Not generated yet. Click Generate to call the active LLM provider with the configured prompt.

Keep exploring

More patents asserted by Novartis Pharmaceuticals Corp.

This patent in court (1)

1 tracked lawsuit name US 10543179.